심혈관 및 연조직 수복 패치 시장 예측(-2030년) : 제품 유형별, 재료 유형별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Cardiovascular & Soft Tissue Repair Patch Market is accounted for $5.0 billion in 2024 and is expected to reach $9.0 billion by 2030 growing at a CAGR of 10.1% during the forecast period. Cardiovascular and Soft Tissue Repair Patches are medical devices used in surgical procedures to repair damaged or weakened tissues in the cardiovascular system or soft tissues elsewhere in the body. These patches are typically made from biocompatible materials, such as synthetic polymers or biological tissues, that are compatible with the body's natural healing processes. In cardiovascular surgeries, these patches are commonly used to repair defects in the heart's walls, such as septal defects or congenital heart defects, or to reinforce weakened areas of blood vessels, such as aneurysms or arteriotomies.

According to the article published by PubMed Central in August 2021, a cross-sectional study was performed on 500 participants in Saudi Arabia, which showed that the prevalence of abdominal hernia was 38.8 percent and the participants in 18-25 years had less prevalence of 21.2 percent.

Market Dynamics:

Driver:

Rising prevalence of cardiovascular disease and soft tissue injuries

Cardiovascular diseases, including heart attacks and congenital heart defects, becoming increasingly common due to factors like aging populations, lifestyle changes, and genetic predispositions, there is a growing demand for effective surgical interventions. Similarly, the incidence of soft tissue injuries, such as hernias and abdominal wall defects, is on the rise due to factors like increased physical activity and trauma. This surge in medical conditions requiring surgical repair boosts the demand for advanced repair patches. These patches offer reliable solutions for reinforcing or replacing damaged tissues, enhancing surgical outcomes and patient recovery driving the markets growth.

Restraint:

High cost of procedures

Advanced medical devices often come with substantial costs due to the sophisticated materials and technologies involved in their development and manufacturing. Consequently, the overall expense of surgical procedures using these patches can be prohibitive for many patients, particularly those without adequate health insurance coverage or in regions with limited healthcare funding. Therefore, the financial challenges associated with these procedures hinder the widespread adoption and growth of the cardiovascular and soft tissue repair patch market.

Opportunity:

Advancements in material science and technology

Innovations in biocompatible materials, such as bioengineered tissues, synthetic polymers, and nanomaterials, have led to the development of more effective, durable, and versatile repair patches. These cutting-edge materials improve the patches' ability to integrate with natural tissues, reduce the risk of rejection, and enhance the overall healing process. In addition technological advancements have also enabled the creation of patches with specialized features, such as drug-eluting properties, which can deliver medications directly to the repair site to prevent infection and promote healing leading to increased adoption and expanded use of cardiovascular and soft tissue repair patches.

Threat:

Stringent regulatory requirements

Regulatory agencies, such as the FDA and EMA, impose rigorous standards for safety, efficacy, and quality, requiring extensive clinical testing and documentation. This leads to prolonged development timelines and increased costs for manufacturers, who must invest significant resources to meet these stringent criteria. As a result, stringent regulatory requirements can limit the availability of new and improved cardiovascular and soft tissue repair patches, hindering market growth and delaying patient access to cutting-edge treatments.

Covid-19 Impact

Initially, lockdowns and resource allocation towards COVID-19 cases led to a decline in elective surgeries, including those requiring repair patches. This caused a temporary dip in market growth. However, as healthcare systems adapted, procedures resumed, and the market recovered. The focus on hygiene might have also driven aseptic patch adoption. Overall, after a temporary setback, the market is expected to return to its pre-pandemic growth trajectory, fueled by the rising prevalence of cardiovascular diseases and advancements in patch technology.

The cardiac patches segment is expected to be the largest during the forecast period

The cardiac patches is expected to be the largest during the forecast period as cardiac patches are often used in minimally invasive heart surgeries. This minimally invasive approach is a major trend in cardiovascular treatments, and cardiac patches play a key role in facilitating it. As minimally invasive procedures become more prevalent, the demand for cardiac patches is expected to rise. Moreover, effective cardiac patches can promote tissue regeneration, improve heart function, and reduce complications. This translates to better patient outcomes, leading to a higher adoption rate by surgeons and increased demand for these patches.

The vascular repair & reconstruction segment is expected to have the highest CAGR during the forecast period

The vascular repair & reconstruction segment is expected to have the highest CAGR during the forecast period because these procedures necessitate strong, durable, and biocompatible patches that can withstand the pressure of blood flow. This drives innovation in patch materials, with a focus on functionalities specifically suited for vascular applications. Further it also encompasses various procedures, from treating aneurysms to peripheral artery disease. The need for different patch types based on the specific application creates a diversified market for various patch technologies.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to the rising prevalence of cardiac diseases, the presence of a large number of pharmaceutical companies, growing research and development expenditure, and increasing incidences of hernia disorders. For instance, according to data from the Centers for Disease Control and Prevention in July 2022, heart disease is one of the leading causes of death in the United States. Among all the heart diseases coronary heart disease is the most common type of heart disease and about 20.1 million adults age 20 and older have coronary heart disease in the United States drives the growth of the market in this region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period owing to rapid developments in healthcare infrastructure, growing trends of minimally invasive surgical procedures, rising incidence of cardiac disease, increasing medical tourism, rapid economic expansion in several countries such as China and India, rising geriatric population, and increasing burden of chronic disorders, Asia Pacific is expected to register the fastest growing rate in the coming years. Additionally raising awareness about the importance of early diagnosis and detection of congenital cardiac disorders, as well as quick treatment propels the market.

Key players in the market

Some of the key players in Cardiovascular & Soft Tissue Repair Patch market include Abbott, Admedus, Atriummed, B.Braun, Bard Peripheral Vascular Inc., Baxter, CorMatrix, Cryolife, Inc., Edwards Life Sciences Corporation, Glycar SA Pty Ltd., Integra LifeSciences Corporation, LabCor, LeMaitre Vascular Inc., Maverick Bioscience, Neovasc, Novomedics, Southern Lights Biomaterials, TEI Biosciences Inc., Terumo Medical Corporation and W.L. Gore & Associates, Inc.

Key Developments:

In April 2024, Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit(TM) BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK).

In April 2024, Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive. The Vantive mission, Extending Lives, Expanding Possibilities, will guide and inspire the proposed company, which will focus on vital organ therapies for acute and chronic kidney diseases and beyond.

In March 2024, Abbott, and the Real Madrid Foundation announced the extension of their partnership through Real Madrid's 2026-27 season. Abbott will remain Global Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation.

Product Types Covered:

• Vascular Patches
• Cardiac Patches
• Orthopedic Repair Patches
• Dural Repair Patches
• Hernia Repair Patches
• Breast Reconstruction Patches
• Other Product Types

Material Types Covered:

• Biologic Patches
• Synthetic Patches

Applications Covered:

• Vascular Repair & Reconstruction
• Aneurysm Repair
• Pericardial Repair
• Dural Repair
• Soft Tissue Repair
• Cardiac Repair
• Other Applications

End Users Covered:

• Ambulatory Surgical Centers (ASCs)
• Hospitals
• Specialty Clinics
• Research & Academic Institutions
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cardiovascular & Soft Tissue Repair Patch Market, By Product Type

• 5.1 Introduction
• 5.2 Vascular Patches
• 5.3 Cardiac Patches
• 5.4 Orthopedic Repair Patches
• 5.5 Dural Repair Patches
• 5.6 Hernia Repair Patches
• 5.7 Breast Reconstruction Patches
• 5.8 Other Product Types

6 Global Cardiovascular & Soft Tissue Repair Patch Market, By Material Type

• 6.1 Introduction
• 6.2 Biologic Patches
  • 6.2.1 Xenografts
  • 6.2.2 Allografts
• 6.3 Synthetic Patches
  • 6.3.1 Polytetrafluoroethylene (PTFE)
  • 6.3.2 Polyester
  • 6.3.3 Polypropylene
  • 6.3.4 Other Synthetic Patches

7 Global Cardiovascular & Soft Tissue Repair Patch Market, By Application

• 7.1 Introduction
• 7.2 Vascular Repair & Reconstruction
• 7.3 Aneurysm Repair
• 7.4 Pericardial Repair
• 7.5 Dural Repair
• 7.6 Soft Tissue Repair
• 7.7 Cardiac Repair
  • 7.7.1 Congenital Heart Defects
  • 7.7.2 Valve Repair
• 7.8 Other Applications

8 Global Cardiovascular & Soft Tissue Repair Patch Market, By End User

• 8.1 Introduction
• 8.2 Ambulatory Surgical Centers (ASCs)
• 8.3 Hospitals
• 8.4 Specialty Clinics
• 8.5 Research & Academic Institutions
• 8.6 Other End Users

9 Global Cardiovascular & Soft Tissue Repair Patch Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Abbott
• 11.2 Admedus
• 11.3 Atriummed
• 11.4 B.Braun
• 11.5 Bard Peripheral Vascular Inc.
• 11.6 Baxter
• 11.7 CorMatrix
• 11.8 Cryolife, Inc.
• 11.9 Edwards Life Sciences Corporation
• 11.10 Glycar SA Pty Ltd.
• 11.11 Integra LifeSciences Corporation
• 11.12 LabCor
• 11.13 LeMaitre Vascular Inc.
• 11.14 Maverick Bioscience
• 11.15 Neovasc
• 11.16 Novomedics
• 11.17 Southern Lights Biomaterials
• 11.18 TEI Biosciences Inc.
• 11.19 Terumo Medical Corporation
• 11.20 W.L. Gore & Associates, Inc.